Ankit Anand, MD
Hematology & Oncology · Farmington, NMNPI 1225383359
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (31.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Bayer at 42.9% of the total. Reporting peaked in 2019 at $8,433 and has fallen 96.7% since, to $280 in 2025.
Across 212 payments — averaging $75.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$7K
- Exelixis Inc.$4K
- Gilead$1K
- Macrogenics, Inc.$1K
- Novartis$316
- Genentech USA, Inc.$178
- plus $2K from 35 others
Across 6 payments — averaging $10,178 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$61K
What the payments were for
- Consulting fees$5,00031%
- Speaking & faculty fees$3,53322%
- Travel & lodging$3,69223%
- Food & beverage$3,84924%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 17 | $6,902 |
| Exelixis Inc. | 21 | $4,204 |
| Gilead | 16 | $1,339 |
| Macrogenics, Inc. | 1 | $1,083 |
| Novartis | 19 | $316 |
| Genentech USA, Inc. | 13 | $178 |
| Merck | 11 | $176 |
| E.r. Squibb & Sons, L.L.C. | 16 | $161 |
| Johnson & Johnson | 8 | $152 |
| Pfizer | 6 | $140 |
| Amgen | 8 | $138 |
| AstraZeneca(2 entities) | 8 | $132 |
| Bristol Myers Squibb | 7 | $121 |
| Astellas Pharma US Inc | 6 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $85 |
| Sanofi | 4 | $72 |
| Puma Biotechnology, Inc. | 5 | $71 |
| Seagen Inc. | 4 | $57 |
| Eisai Inc. | 3 | $54 |
| Verastem, Inc. | 3 | $49 |
| Incyte Corporation | 3 | $48 |
| Daiichi Sankyo Inc. | 3 | $44 |
| Boehringer Ingelheim | 2 | $40 |
| Spectrum Pharmaceuticals Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $38 |
| Roche Diagnostics Corporation | 1 | $36 |
| Taiho Oncology, Inc. | 2 | $36 |
| Rigel Pharmaceuticals, Inc. | 2 | $34 |
| Recordati_rare_diseases_inc. | 1 | $29 |
| Ipsen Biopharmaceuticals, Inc | 2 | $28 |
| AVEO Pharmaceuticals, Inc. | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Array Biopharma Inc | 1 | $17 |
| AbbVie | 1 | $16 |
| Dova Pharmaceuticals | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Novocure Inc. | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $13 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| EMD Serono, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,098 in reported general payments places this provider in the 85th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 15 | $198,564 |
| TagrissoOsimertinib Mesylate | 12 | $190,740 |
| Abiraterone Acetate | 41 | $179,090 |
| XareltoRivaroxaban | 27 | $33,017 |
| EliquisApixaban | 28 | $32,751 |
| Anastrozole | 52 | $1,674 |
| Fentanyl | 11 | $987 |
| Letrozole | 25 | $565 |
| Hydroxyurea | 18 | $458 |
| Prednisone | 68 | $413 |
| Oxycodone Hcl | 18 | $408 |
| Prochlorperazine Maleate | 11 | $404 |
| Ondansetron Hcl | 16 | $196 |
| Potassium Chloride | 15 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $152 | $231,58142 claims |
| AstraZenecaTagrisso | $132 | $190,74012 claims |
| PfizerEliquis | $140 | $32,75128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 54 hematology & oncology providers in New Mexico.
Other hematology & oncology in Farmington
- Sardar ImamFarmington$24K
- Jeffrey NeidhartFarmington$6K
- James NeidhartFarmington$11
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- George AtwehAlbuquerque$24K
- Ethan BinderRio Rancho$16K
- Scott HerbertAlbuquerque$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.